CN Bio has introduced the PhysioMimix® DILI Assay Kit: Human 24, a next-generation Organ-on-a-Chip (OOC) system designed to provide robust human-specific insights into drug-induced liver injury (DILI). Built upon CN Bio’s FDA-recognized liver microphysiological system (MPS), this kit streamlines drug safety testing, addressing key limitations of traditional preclinical models.

Addressing Drug-Induced Liver Injury in Drug Development

Liver toxicity remains a major cause of drug failure, with 18% of clinical trial failures linked to hepatotoxicity. Conventional in vitro, in vivo, and in silico models often fail to capture the complex physiological responses seen in human liver tissue. CN Bio’s liver MPS overcomes these limitations by integrating highly functional hepatic tissues with Kupffer cells, allowing for more accurate and clinically translatable hepatotoxicity assessments.

Key Features of the PhysioMimix® DILI Assay Kit: Human 24

• Human-relevant hepatotoxicity testing using primary liver cells and Kupffer cells
• 24-well format enables simultaneous screening of up to eight conditions in triplicate
• Extended culture duration (up to two weeks) for evaluating long-term toxicity effects
• Enhanced detection of complex DILI mechanisms, including immune-mediated responses
• Ready-to-use format eliminates the need for extensive model development and validation

Revolutionizing Preclinical Toxicology Workflows

Initially available as a contract research service (CRS), CN Bio’s DILI assay is now accessible as a complete kit, enabling rapid adoption by pharmaceutical and biotech labs. This innovation helps researchers identify flawed drug candidates earlier, improving decision-making and reducing costly late-stage failures.